Molecular Target

 
News Articles for Molecular Target top ^
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced the acceptance of two abstracts for poster presentations relating to RXDX-101, the company’s proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
Sign-up for Ignyta Announces RXDX-101 Presentations at the 2014 EORTC-NCI-AACR ‘Molecular Targets and Cancer Therapeutics’ Conference investment picks
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced four poster presentations at the 26 th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place November 18 - 21, 2014, in Barcelona, Spain.
Sign-up for Verastem Presents Data at the 2014 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics investment picks
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced scheduled poster presentations at the 26 th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place November 18 - 21, 2014, in Barcelona, Spain.
Sign-up for Verastem to Present Data at the 2014 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics investment picks
Clinical data from Phase 1 studies of MM-398 and MM-151 presented BARCELONA, Spain, Nov.
Sign-up for Merrimack Pharmaceuticals Presents on Multiple Programs at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics investment picks
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that its Chief Medical Officer, Adrian Senderowicz, M.D., has been selected to serve as Workshop Planning Committee Chair for the workshop entitled Policy Issues in the Development and Adoption of Molecularly Targeted Therapies for Cancer .
Sign-up for Ignyta to Chair the Institute of Medicine’s National Cancer Policy Forum Workshop on Molecularly Targeted Cancer Therapies investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Molecular Target
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Moduslink Global Solutions  |  Next: Molina Healthcare